Australian Public Assessment Report for Rituximab

The Australian-sourced MabThera was not used, and no data were provided to verify the comparability of the various sources of MabThera. Provided adequate comparability of the EU/US sourced and Australian sourced versions of MabThera is demonstrated in the quality module, the submitted non-clinical dossier is considered adequate. ................
................